| Literature DB >> 16499290 |
Abstract
ID Biomedical, under license from the University of Tennessee, is developing StreptAvax, a potential subunit vaccine against group A streptococcal infection. By January 2005, analysis of data from phase II clinical trials conducted in adults was completed. Pediatric trials are not expected to begin before 2007.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16499290
Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472